LEADER 01491nam  2200433   450 
001 9910707364703321
005 20160715104931.0
035   $a(CKB)5470000002463870
035   $a(OCoLC)953619871
035   $a(OCoLC)995470000002463870
035   $a(EXLCZ)995470000002463870
100   $a20160715d1990      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 10$aPerspectives of drug manufacturers $eabbreviated new drug applications
210  1$a[Washington, D.C.] :$cDepartment of Health and Human Services, Office of Inspector General, Office of Evaluation and Inspections,$d1990.
215   $a1 online resource (27 unnumbered pages) $cillustrations
300   $aTitle from title screen (viewed July 14, 2016).
300   $a"February 1990."
300   $a"OEI-12-90-00770."
320   $aIncludes bibliographical references (page 15).
517   $aPerspectives of drug manufacturers 
606   $aGeneric drugs$zUnited States
606   $aPharmaceutical policy$zUnited States
606   $aDrug approval$zUnited States
606   $aPharmaceutical industry$zUnited States
615  0$aGeneric drugs
615  0$aPharmaceutical policy
615  0$aDrug approval
615  0$aPharmaceutical industry
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910707364703321
996   $aPerspectives of drug manufacturers$93487044
997   $aUNINA